Science
GLP-1 Rebound Weight: Why It Happens, and How to Get Ahead of It

“Rebound weight” is the term for the regain that tends to follow stopping a GLP-1. It's real, it's common, and — this is the part that matters — it isn't a sign you did anything wrong. Understanding the mechanism turns it from a personal verdict into a predictable event you can plan around. Our staying-off guide is the practical companion to this explainer.
What rebound actually is
GLP-1 medication reduces appetite by acting on the gut-hormone signals that regulate hunger and fullness — the same signals behind what many people call food noise. When the medication leaves your system, those signals return, and with them the appetite that was quieted. That's the engine of rebound: not a collapse of discipline, but biology resuming its default. We cover the appetite mechanism in how GLP-1s change cravings and appetite.
What the evidence shows
In the STEP-1 extension, people who stopped semaglutide regained about two-thirds of their lost weight within a year, and a 2026 meta-analysis puts the one-year figure near 60% of lost weight across studies. Those are averages, not destiny — the range around them is wide, and the habits you keep after stopping are a large part of where you land within it.
Why it isn't failure
Obesity behaves like a chronic condition, and chronic conditions tend to return when treatment stops — the same way blood pressure rises again off medication. Framing rebound as a moral failing is both wrong and counterproductive; framing it as a biological signal is what lets you respond early.
The early-warning signals
- Food noise returning — usually the first sign, often before the scale moves.
- A trend, not a day: three to five pounds trending up over a month is worth acting on.
- Changes in energy, strength, or how clothes fit, which can flag lost muscle the scale hides.
Getting ahead of it
The levers that blunt rebound are the maintenance basics: a protein floor, resistance training to hold muscle, protected sleep, and a weekly weigh-in as an early-warning system — plus an early line back to a provider if the trend turns. Our maintenance playbook lays them out, and the staying-off guide covers the whole window, including when restarting is the right call.
Keep reading
This article is for informational purposes only and does not constitute medical advice. Compounded tirzepatide is not FDA-approved. A licensed provider determines whether treatment is appropriate for you. Read how we source and review content and the references behind the clinical figures used on this site.